Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear.
Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings were presented at ASN Kidney Week 2024 October 23–27.
For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over a one-year period.
Among 14,783 patients, 9% were treated with a GLP-1RA while taking anti-cancer drugs. AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure.
“Given the cardiovascular and anti-diabetic benefits of GLP-IRA, we suggest that these agents can be safely continued during administration of anti-cancer therapy,” said corresponding author Swetha Rani Kanduri, MD, of Ochsner Health.
“We invite prospective studies to further elaborate on the effects of GLP1-RA in patients with cancer.”
More information:
Study: “Exposure to Glucagon Like Peptide 1 Receptor Agonists (GLP-1RA) Does Not Increase the Risk of AKI Associated with Anti-Cancer Therapy”
Citation:
Do certain diabetes drugs increase the risk of acute kidney injury in patients taking anti-cancer therapies? (2024, October 25)
retrieved 26 October 2024
from https://medicalxpress.com/news/2024-10-diabetes-drugs-acute-kidney-injury.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
